ClinicalTrials.gg
CompletedNCT00422227Updated Aug 30, 2010Results posted

Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region

A Phase 4 interventional study of Etanercept , Methotrexate and Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide in Rheumatoid Arthritis, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 27 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2010-08-30.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies testing etanercept in Arthritis, Rheumatoid — 4 open to participants now, 5 under way, 1 of them phase 3. Etanercept · Arthritis, Rheumatoid.

Enrollment
17th of 69
300 · median 144
Started
2007
with 4 others
Phase 4
39 of 69
1 open now
Registered
18th of 69
by date
Lead sponsor
10 of 69
Wyeth is now a wholly owned subsidiary of Pfizer

Among the 69 studies testing etanercept in Arthritis, Rheumatoid, this one is the 17th largest by enrollment, is one of 5 that started in 2007, is one of 39 in phase 4, and was the 18th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 69 studies testing etanercept in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About etanercept

Etanercept: first FDA approval 1998 (ENBREL), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing etanercept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy of etanercept with usual disease-modifying anti-rheumatic drug (DMARD) therapy in the treatment of moderate to severe rheumatoid arthritis (RA) over 16 weeks in the Asia Pacific region.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of RA
  • Currently receiving an adequate dose of methotrexate (MTX) for treatment of RA
  • Active RA at time of screening and baseline

Exclusion criteria

Exclusion Criteria:

  • Previous or current treatment with etanercept (ETN), other tumor necrosis factor-alpha inhibitors, or other biologic agents
  • Concurrent treatment with a DMARD, other than MTX, at screening
  • Receipt of any DMARD, other than MTX, within 3 months before screening
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (actual)

Study arms

  • Active comparator
    1

    Etanercept + Methotrexate

    Drug: Etanercept , Methotrexate

  • Active comparator
    2

    DMARD therapy Methotrexate + Sulfasalazine/Hydroxychloroquine/Leflunomide

    Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide

Interventions

  • DrugEtanercept , Methotrexate

    Drug pages: Etanercept · Methotrexate

    * Etanercept: 25 mg twice weekly over 16 weeks, SC * Methotrexate: \> 7.5 mg/week and no more than 25 mg/week, PO

  • DrugMethotrexate; sulfasalazine; hydroxychloroquine;leflunomide

    Drug pages: Methotrexate · Sulfasalazine · Hydroxychloroquine · Leflunomide

    * Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO * Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO * Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day * Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Adjusted Mean of American College of Rheumatology Response (ACR-N) Area Under Curve (AUC) Over 16 Weeks

    ACR-N = the lowest of 3 values (percent change in the number of swollen joints, percent change in the number of tender joints, and median of the other 5 measures in the ACR core data set). Negative numbers indicate worsening. The ACR-N AUC was calculated using the trapezoidal rule as the ACR-N multiplied by the duration of the assessment period (in weeks) and was presented as %-weeks.

    Time frame: 16 weeks

Secondary outcomes

  1. Percentage of Participants Achieving ACR 20, 50, and 70 Responses

    Response includes improvement in tender or swollen joints as well as 20 percent improvement in three of the other five criteria. Required: ≥ 20%, 50% or 70% improvement in tender joint count ≥ 20% , 50% or 70% improvement in swollen joint count and at least 20%, 50%, 70% improvement in 3 of the following 5:Patient pain assessment , Patient global assessment ,Physician global assessment, Patient self-assessed disability.

    Time frame: Week 16

  2. Percentage of Participants Achieving DAS28 <3.2 (Low Disease Activity) and <2.6 (Remission)

    Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR)) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm).

    Time frame: Week 16

  3. Percent Change From Baseline in DAS28 at Week 16

    Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR)) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm).

    Time frame: Week 16

  4. Percentage of Participants Achieving European League Against Rheumatism (EULAR) Moderate or Good Response

    EULAR Response Criteria DAS28) improvement at week 16. Good response was defined as \>1.2 improvement in DAS from Baseline and DAS attained during follow-up of ≤2.4. Non-responders were participants with improvement of ≤0.6 or participants with improvement of \>0.6 but ≤1.2 and DAS attained during follow-up of \>3.7. Remaining participants were classified as moderate. Scores of good and moderate were considered to have therapeutic response.

    Time frame: Week 16

  5. Percentage of Participants With DAS28 Improvement of ≥0.6 and ≥1.2

    Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm).

    Time frame: Week 16

  6. Percent Change From Baseline in Painful and Swollen Joint Counts

    Participant's assessment of pain - A horizontal pain visual analog scale (VAS) (0-100 mm) is used to assess the participants current level of pain; 0 = no pain and 100 = worst pain. Swollen joint count - ACR swollen joint count, an assessment of 28 joints. Joints are classified as either swollen or not swollen.

    Time frame: Week 2, 4, 8, 12, 16

  7. Percent Change From Baseline in Physician And Subject Global Assessments

    The Physician Global Assessment of Disease Activity: The participant's disease activity is estimated over the last two - three days by the physician; A zero (0) means no disease activity and a ten (10) means extreme disease activity. The Subject Global Assessment of Disease Activity: The participant assesses overall arthritis activity. A zero (0) means no disease activity and a ten (10) means extreme disease activity.

    Time frame: Week 2, 4, 8, 12, 16

  8. Percent Change From Baseline in Duration (Minutes) of Morning Stiffness

    The duration of morning stiffness on the day of examination should be determined by asking the following two questions: When did you awaken this morning? When were you able to resume your normal activities without stiffness? Duration of morning stiffness is equal to the time elapsed between the above two times in minutes; If none is present enter 0, If morning stiffness is still continuing, please indicate average of duration of stiffness over the past 3 days. If stiffness persists the entire day 1440 minutes (24h x 60 minutes) should be recorded.

    Time frame: Week 2, 4, 8, 12, 16

  9. Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales

    VAS, participant indicates by marking a vertical line at an appropriate position through a horizontal line. The length of the line measures from left (in mm) and the value (in mm) is recorded. General Health VAS, "in general how would you rate your heath over the last 2-3 weeks", 0mm equals very well and 100mm equals extremely bad. Pain VAS: "indicate the amount of pain experienced during the last 2-3 days", 0 mm equals no pain and 100 mm equals pain as bad as it can be. Fatigue VAS: "how fatigued or tired have you been over the last week", range =No Fatigue - Extremely Fatigued.

    Time frame: Week 2, 4, 8, 12, 16

07

Results

Posted Aug 30, 2010

Participant flow

Subjects were recruited in the Asia-Pacific Region from June 2007 to October 2008.

Participant flow — Overall Study
MilestoneETN/MTXDMARD/MTX
Started197103
Completed19388
Not completed415
Withdrew: Adverse event38
Withdrew: Lost to follow-up13
Withdrew: Withdrawal by subject04

Outcome measures

PrimaryChange From Baseline in Adjusted Mean of American College of Rheumatology Response (ACR-N) Area Under Curve (AUC) Over 16 Weeks

ACR-N = the lowest of 3 values (percent change in the number of swollen joints, percent change in the number of tender joints, and median of the other 5 measures in the ACR core data set). Negative numbers indicate worsening. The ACR-N AUC was calculated using the trapezoidal rule as the ACR-N multiplied by the duration of the assessment period (in weeks) and was presented as %-weeks.

Time frame:
16 weeks
Reported as:
Mean · Units on a scale
Change From Baseline in Adjusted Mean of American College of Rheumatology Response (ACR-N) Area Under Curve (AUC) Over 16 Weeks
Units on a scaleETN/MTXDMARD/MTX
Change From Baseline in Adjusted Mean of American College of Rheumatology Response (ACR-N) Area Under Curve (AUC) Over 16 Weeks434.83 ± 29.18289.54 ± 36.11
Statistical analysis
  • ETN/MTX vs DMARD/MTX · ANOVA · p = <0.001
SecondaryPercentage of Participants Achieving ACR 20, 50, and 70 Responses

Response includes improvement in tender or swollen joints as well as 20 percent improvement in three of the other five criteria. Required: ≥ 20%, 50% or 70% improvement in tender joint count ≥ 20% , 50% or 70% improvement in swollen joint count and at least 20%, 50%, 70% improvement in 3 of the following 5:Patient pain assessment , Patient global assessment ,Physician global assessment, Patient self-assessed disability.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving ACR 20, 50, and 70 Responses
Percentage of ParticipantsETN/MTXDMARD/MTX
ACR 2078.8758.16
ACR 5056.7034.69
ACR 7019.077.14
Statistical analysis
  • ETN/MTX vs DMARD/MTX · Fisher Exact · p = <0.001
  • ETN/MTX vs DMARD/MTX · Fisher Exact · p = <0.001
  • ETN/MTX vs DMARD/MTX · Fisher Exact · p = 0.009
SecondaryPercentage of Participants Achieving DAS28 <3.2 (Low Disease Activity) and <2.6 (Remission)

Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR)) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm).

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving DAS28 <3.2 (Low Disease Activity) and <2.6 (Remission)
Percentage of ParticipantsETN/MTXDMARD/MTX
Low Disease (DAS28 <3.2)39.0918.45
Remission (DAS28 <2.6)15.747.77
Statistical analysis
  • ETN/MTX vs DMARD/MTX · Fisher Exact · p = <0.001
  • ETN/MTX vs DMARD/MTX · Fisher Exact · p = 0.069
SecondaryPercent Change From Baseline in DAS28 at Week 16

Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR)) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm).

Time frame:
Week 16
Reported as:
Number · Percent change
Percent Change From Baseline in DAS28 at Week 16
Percent changeETN/MTXDMARD/MTX
Percent Change From Baseline in DAS28 at Week 1638.3227.46
Statistical analysis
  • ETN/MTX vs DMARD/MTX · ANCOVA · p = <0.001
SecondaryPercentage of Participants Achieving European League Against Rheumatism (EULAR) Moderate or Good Response

EULAR Response Criteria DAS28) improvement at week 16. Good response was defined as \>1.2 improvement in DAS from Baseline and DAS attained during follow-up of ≤2.4. Non-responders were participants with improvement of ≤0.6 or participants with improvement of \>0.6 but ≤1.2 and DAS attained during follow-up of \>3.7. Remaining participants were classified as moderate. Scores of good and moderate were considered to have therapeutic response.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving European League Against Rheumatism (EULAR) Moderate or Good Response
Percentage of ParticipantsETN/MTXDMARD/MTX
Percentage of Participants Achieving European League Against Rheumatism (EULAR) Moderate or Good Response87.8273.79
Statistical analysis
  • ETN/MTX vs DMARD/MTX · Fisher Exact · p = 0.003
SecondaryPercentage of Participants With DAS28 Improvement of ≥0.6 and ≥1.2

Disease Activity Score 28 based on 28 Joints (DAS28) is the calculation of DAS28: DAS28 = 0.56 sqrt (28 painful joint count) + 0.28 sqrt (28 swollen joint count) + 0.70 (ln erythrocyte sedimentation rate (ESR) + 0.014 (General Health) (GH). GH = Subject general health visual analog scale (0-10 mm).

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Percentage of Participants With DAS28 Improvement of ≥0.6 and ≥1.2
Percentage of ParticipantsETN/MTXDMARD/MTX
≥0.691.3778.64
≥1.282.7466.02
Statistical analysis
  • ETN/MTX vs DMARD/MTX · Fisher Exact · p = 0.003
  • ETN/MTX vs DMARD/MTX · Fisher Exact · p = 0.001
SecondaryPercent Change From Baseline in Painful and Swollen Joint Counts

Participant's assessment of pain - A horizontal pain visual analog scale (VAS) (0-100 mm) is used to assess the participants current level of pain; 0 = no pain and 100 = worst pain. Swollen joint count - ACR swollen joint count, an assessment of 28 joints. Joints are classified as either swollen or not swollen.

Time frame:
Week 2, 4, 8, 12, 16
Reported as:
Number · Percent change
Percent Change From Baseline in Painful and Swollen Joint Counts
Percent changeETN/MTXDMARD/MTX
Painful Joints - Week 234.1727.68
Painful Joints - Week 446.1136.71
Painful Joints - Week 855.4849.71
Painful Joints - Week 1265.6555.55
Painful Joints - Week 1668.9957.31
Swollen Joints - Week 238.5921.32
Swollen Joints - Week 449.3327.72
Swollen Joints - Week 859.9144.19
Swollen Joints - Week 1267.9750.48
Swollen Joints - Week 1673.8356.32
Statistical analysis
  • ETN/MTX vs DMARD/MTX · ANCOVA · p = 0.014
  • ETN/MTX vs DMARD/MTX · ANCOVA · p = <0.001
SecondaryPercent Change From Baseline in Physician And Subject Global Assessments

The Physician Global Assessment of Disease Activity: The participant's disease activity is estimated over the last two - three days by the physician; A zero (0) means no disease activity and a ten (10) means extreme disease activity. The Subject Global Assessment of Disease Activity: The participant assesses overall arthritis activity. A zero (0) means no disease activity and a ten (10) means extreme disease activity.

Time frame:
Week 2, 4, 8, 12, 16
Reported as:
Number · Percent change
Percent Change From Baseline in Physician And Subject Global Assessments
Percent changeETN/MTXDMARD/MTX
Physician Global Assessment - Week 230.4011.83
Physician Global Assessment - Week 439.5822.81
Physician Global Assessment - Week 845.8635.41
Physician Global Assessment - Week 1255.0038.67
Physician Global Assessment - Week 1662.0545.04
Subject Global Assessment - Week 221.847.24
Subject Global Assessment - Week 428.9419.22
Subject Global Assessment - Week 834.9226.08
Subject Global Assessment - Week 1243.1830.10
Subject Global Assessment - Week 1650.7630.55
Statistical analysis
  • ETN/MTX vs DMARD/MTX · ANCOVA · p = <0.001
  • ETN/MTX vs DMARD/MTX · ANCOVA · p = <0.001
SecondaryPercent Change From Baseline in Duration (Minutes) of Morning Stiffness

The duration of morning stiffness on the day of examination should be determined by asking the following two questions: When did you awaken this morning? When were you able to resume your normal activities without stiffness? Duration of morning stiffness is equal to the time elapsed between the above two times in minutes; If none is present enter 0, If morning stiffness is still continuing, please indicate average of duration of stiffness over the past 3 days. If stiffness persists the entire day 1440 minutes (24h x 60 minutes) should be recorded.

Time frame:
Week 2, 4, 8, 12, 16
Reported as:
Number · Percent change
Percent Change From Baseline in Duration (Minutes) of Morning Stiffness
Percent changeETN/MTXDMARD/MTX
Week 254.9216.43
Week 463.8533.22
Week 873.4137.35
Week 1279.7652.76
Week 1680.5546.77
Statistical analysis
  • ETN/MTX vs DMARD/MTX · ANCOVA · p = <0.001
SecondaryPercent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales

VAS, participant indicates by marking a vertical line at an appropriate position through a horizontal line. The length of the line measures from left (in mm) and the value (in mm) is recorded. General Health VAS, "in general how would you rate your heath over the last 2-3 weeks", 0mm equals very well and 100mm equals extremely bad. Pain VAS: "indicate the amount of pain experienced during the last 2-3 days", 0 mm equals no pain and 100 mm equals pain as bad as it can be. Fatigue VAS: "how fatigued or tired have you been over the last week", range =No Fatigue - Extremely Fatigued.

Time frame:
Week 2, 4, 8, 12, 16
Reported as:
Number · Percent change
Percent Change From Baseline in General Health, Pain, and Fatigue, Visual Analog Scales
Percent changeETN/MTXDMARD/MTX
General Health - Week 221.148.88
General Health - Week 430.6122.78
General Health - Week 838.5727.86
General Health - Week 1242.1030.26
General Health - Week 1650.4933.89
Pain - Week 227.599.99
Pain - Week 434.7322.98
Pain - Week 842.9729.14
Pain - Week 1248.4633.97
Pain - Week 1654.4236.45
Fatigue - Week 220.906.63
Fatigue - Week 430.8719.00
Fatigue - Week 835.9221.82
Fatigue - Week 1239.6528.65
Fatigue - Week 1646.9230.04
Statistical analysis
  • ETN/MTX vs DMARD/MTX · ANCOVA · p = <0.001
  • ETN/MTX vs DMARD/MTX · ANCOVA · p = <0.001
  • ETN/MTX vs DMARD/MTX · ANCOVA · p = 0.001

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ETN/MTX—6/197 (3%)66/197 (33.5%)
DMARD/MTX—3/103 (2.9%)71/103 (68.9%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventETN/MTXDMARD/MTX
Pneumonia bacterialInfections and infestations0/1971/103
Alanine aminotransferase increasedInvestigations0/1971/103
Aspartate aminotransferase increasedInvestigations0/1971/103
Transaminases increasedInvestigations0/1971/103
Myocardial infarctionCardiac disorders1/1970/103
Gastrointestinal haemorrhageGastrointestinal disorders1/1970/103
Non-cardiac chest painGeneral disorders1/1970/103
CellulitisInfections and infestations1/1970/103
Herpes zosterInfections and infestations1/1970/103
Pneumocystis jiroveci pneumoniaInfections and infestations1/1970/103
Most frequent other events
Most frequent other events
EventETN/MTXDMARD/MTX
Upper respiratory tract infectionInfections and infestations27/19716/103
Alanine aminotransferase increasedInvestigations11/19715/103
Aspartate aminotransferase increasedInvestigations7/19711/103
LeukopeniaBlood and lymphatic system disorders4/1978/103
NauseaGastrointestinal disorders4/1978/103
CoughRespiratory, thoracic and mediastinal disorders7/1977/103
PyrexiaGeneral disorders6/1976/103

Baseline characteristics

Age Continuous
Age Continuous(years)ETN/MTXDMARD/MTXTotal
Mean48.38 ± 11.9848.52 ± 11.2548.43 ± 11.72
Sex: Female, Male
Sex: Female, Male(Participants)ETN/MTXDMARD/MTXTotal
Female18091271
Male171229
08

Study locations

27 sites
  • Hong Kong, Hong Kong
  • Bangalore, 560017, India
  • Bangalore, 560034, India
  • Hyderabaad, 500082, India
  • New Delhi, 110029, India
  • In Cheon, Korea 400-711, Korea, Republic of
  • Seoul, Korea 110-744, Korea, Republic of
  • Seoul, Korea 120-752, Korea, Republic of
  • Seoul, Korea 133-792, Korea, Republic of
  • Seoul, Korea 137-701, Korea, Republic of
  • Seoul, Korea 138-736, Korea, Republic of
  • Ipoh, Perak, 30450, Malaysia
  • Kuala Lumpur, 68100, Malaysia
  • Pulau Pinang, 10450, Malaysia
  • Putrajaya, 62250, Malaysia
  • Seremban, 70300, Malaysia
  • Cebu, 6000, Philippines
  • Makati City, 1200, Philippines
  • Manila, 1000, Philippines
  • Manila, 1004, Philippines
  • Manila, 1500, Philippines
  • Quezon City, 1102, Philippines
  • Singapore, 308433, Singapore
  • Kaohsiung City, 807, Taiwan
  • Taipei, 100, Taiwan
  • Taipei, 112, Taiwan
  • Bangkok, 10400, Thailand
09

References and documents

Publications

  • Fleischmann R, Koenig AS, Szumski A, Nab HW, Marshall L, Bananis E. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis. Rheumatology (Oxford). 2014 Nov;53(11):1984-93. doi: 10.1093/rheumatology/keu235. Epub 2014 Jun 6. PubMed 24907147 ↗
  • Bae SC, Gun SC, Mok CC, Khandker R, Nab HW, Koenig AS, Vlahos B, Pedersen R, Singh A. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskelet Disord. 2013 Jan 8;14:13. doi: 10.1186/1471-2474-14-13. PubMed 23294908 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2007
First posted
Jan 15, 2007
Start
Jun 2007
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results first posted
Aug 30, 2010
Last update
Aug 30, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00422227
First posted
Jan 15, 2007
Start date
Jun 2007
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Aug 30, 2010
Last update
Aug 30, 2010

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
Trial Manager
principal investigator · For Hong Kong: medinfo@wyeth.com
Trial Manager
principal investigator · For Taiwan: medinfo@wyeth.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Etanercept · Methotrexate · Sulfasalazine · Hydroxychloroquine · Leflunomide

Start the discussion